Tuesday, September 20, 2011
Spinifex Pharmaceuticals Pty. Ltd., of Victoria, Australia, said the first patients have been treated in its Phase II trial of EMA401, an angiotensin II Type II receptor antagonist, in postherpetic neuralgia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.